Search Results

TPG and AmerisourceBergen Corporation (NYSE: ABC) today announced the completion of their previously announced acquisition of OneOncology, a network of leading oncology practices.

With the help of third-party investors, the new venture will focus on three genetic and rare diseases: tuberous sclerosis complex, erythropoietic protoporphyria and alpha-A1 antitrypsin deficiency.

TPG (NASDAQ: TPG), a global alternative asset management firm, and AmerisourceBergen Corporation (NYSE: ABC) today announced that they have agreed to acquire OneOncology, a network of leading oncology practices, from General Atlantic, a leading global growth equity firm.

JOGO Health, a medtech company treating chronic pain and neuromuscular disorders, announced it has closed over $5.5 million in an investment round led by Hourglass Ventures.

Sudo Biosciences announced the close of a $116 million Series B financing round co-led by Enavate Sciences and TPG, which is investing in the company through TPG Life Sciences Innovations and The Rise Fund, with participation from Sanofi Ventures, Surveyor Capital, Monograph Capital, and Eventide Asset Management as well as existing investors Frazier Life Sciences and Velosity Capital.

Saluda Medical Inc. announced the closing of a US $150 million equity financing round led by new investor Wellington Management, with strong support from current investor Fidelity Management & Research Company and new investor TPG.

Integrated Biosciences today announced they have joined Illumina Ventures Labs to integrate the company’s drug discovery engine with Illumina sequencing.

VenoStent, Inc. announced that it closed an additional $4 million from Norwest Venture Partners to round out its Series A financing at $20 million with Good Growth Capital and IAG Capital Partners co-leading the deal.

BioSyent Inc. is pleased to announce that it has been named to the 2024 TSX Venture 50 list as one of the top performers on the TSX Venture Exchange.